Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Acro Biomedical (ACBM) Payables (2016 - 2025)

Acro Biomedical has reported Payables over the past 10 years, most recently at $55550.0 for Q4 2025.

  • Quarterly results put Payables at $55550.0 for Q4 2025, down 64.04% from a year ago — trailing twelve months through Dec 2025 was $55550.0 (down 64.04% YoY), and the annual figure for FY2025 was $55550.0, down 64.04%.
  • Payables for Q4 2025 was $55550.0 at Acro Biomedical, down from $116582.0 in the prior quarter.
  • Over the last five years, Payables for ACBM hit a ceiling of $155507.0 in Q3 2024 and a floor of $12072.0 in Q2 2021.
  • Median Payables over the past 5 years was $95493.0 (2025), compared with a mean of $91025.6.
  • Biggest five-year swings in Payables: surged 1026.12% in 2021 and later tumbled 64.04% in 2025.
  • Acro Biomedical's Payables stood at $26197.0 in 2021, then surged by 192.29% to $76571.0 in 2022, then surged by 101.7% to $154444.0 in 2023, then grew by 0.01% to $154460.0 in 2024, then tumbled by 64.04% to $55550.0 in 2025.
  • The last three reported values for Payables were $55550.0 (Q4 2025), $116582.0 (Q3 2025), and $95493.0 (Q2 2025) per Business Quant data.